Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect and safety of erlotinib versus NVB plus
cisplatin (NP) as adjuvant treatment in patients with stage IIIA NSCLC after complete
resection with EGFR activating mutations and to explore a new treatment strategy for this
subset.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Lung Cancer Surgical Group
Collaborators:
Beijing Cancer Hospital Chinese PLA General Hospital Fudan University Harbin Medical University Hebei Medical University Fourth Hospital Qingdao University Sun Yat-sen University The First Affiliated Hospital of Soochow University The Second People's Hospital of Sichuan Tianjin Medical University Cancer Institute and Hospital Zhejiang Cancer Hospital